Loading...
Loading...

Go to the content (press return)

Bivalent chromatin as a therapeutic target in cancer: an in silico predictive approach for combining epigenetic drugs

Author
Alarcón, T.; Sardanyes, J.; Guillamon, A.
Type of activity
Journal article
Journal
PLoS computational biology
Date of publication
2021-06-01
Volume
17
Number
6
First page
e1008408
DOI
10.1371/journal.pcbi.1008408
Project funding
Development of novel mathematical and experimental methodologies to control neuronal activity and dissect spatio-temporal neuronal codes
Dynamics Associated to Connections Between Invariant objects with Applications to Neuroscience and Mechanics
Multiscale modelling and analysis in systems biology and biomedicine
Sistemes dinàmics
Repository
http://hdl.handle.net/2117/352573 Open in new window
URL
https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1008408 Open in new window
Abstract
Tumour cell heterogeneity is a major barrier for efficient design of targeted anti-cancer therapies. A diverse distribution of phenotypically distinct tumour-cell subpopulations prior to drug treatment predisposes to non-uniform responses, leading to the elimination of sensitive cancer cells whilst leaving resistant subpopulations unharmed. Few strategies have been proposed for quantifying the variability associated to individual cancer-cell heterogeneity and minimizing its undesirable impact on...
Citation
Alarcón, T.; Sardanyes, J.; Guillamon, A. Bivalent chromatin as a therapeutic target in cancer: an in silico predictive approach for combining epigenetic drugs. "PLoS computational biology", 1 Juny 2021, vol. 17, núm. 6, p. e1008408.
Group of research
SD - UPC Dynamical Systems

Participants

Attachments